OPKO Health (OPK) Q3 2025 earnings summary

Executive summary

• Completed sale of BioReference oncology assets to Labcorp for $192.5 million upfront, up to $32.5 million in earnouts, and recognized a $101.6 million gain, streamlining operations and supporting share repurchases.

• Entered a research collaboration with Regeneron for multispecific antibodies, with potential milestones exceeding $1 billion.

• Advanced pharmaceutical pipeline with four clinical candidates, including Merck's EBV vaccine and ModeX programs, and presented positive preclinical data for oral GLP-1/GLP-2.

• Repurchased $73.8 million in stock as of September 30, 2025, with $126 million remaining authorized; nearly 25 million shares repurchased YTD.

• Maintained strong cash position of $428.9 million at quarter-end, supported by asset sales and investment proceeds.

Financial highlights

• Q3 2025 total revenue was $151.7 million, down from $173.6 million in Q3 2024; diagnostics revenue was $95.2 million (including $19.5 million from sold oncology assets).

• Operating income for Q3 2025 was $48.1 million, up from $14.2 million in Q3 2024, driven by the gain on asset sale.

• Net income for Q3 2025 was $21.6 million ($0.03/share), compared to $24.9 million ($0.04/share) in Q3 2024.

• Pharmaceutical segment Q3 revenue from products was $37.7 million, with Rayaldee sales up to $7.5 million; operating loss improved to $24.2 million.

• Gross margin and operating margin improved due to cost reductions and asset sales.

Outlook and guidance

• Q4 2025 revenue expected between $135 million-$140 million; service revenue $70 million-$75 million, product revenue $40 million-$45 million, other revenue $25 million-$30 million.

• Total costs and expenses for Q4 expected at $175 million-$180 million; R&D expense $30 million-$35 million; D&A expense ~$24 million.

• 2026 guidance: BioReference to grow revenue low single digits and achieve profitability; pharmaceutical business to grow mid-single digits and improve operating income by low double digits.

• Ngenla profit share payments expected to rise to $32 million-$35 million in 2026.

• Up to $100 million planned R&D investment in 2026, with up to six phase I programs enrolling.